The Journal of Urology
Volume 183, Issue 1 , Pages 339-344 , January 2010

Bikunin Loss in Urine as Useful Marker for Bladder Carcinoma

  • Ke-Hung Tsui

      Affiliations

    • Chang Gung Bioinformatics Center, Department of Urology, Chang Gung Memorial Hospital, Taiwan, Republic of China
    • Equal study contribution.
    • ,
  • Petrus Tang

      Affiliations

    • Chang Gung Bioinformatics Center, Department of Urology, Chang Gung Memorial Hospital, Taiwan, Republic of China
    • Equal study contribution.
    • ,
  • Chiao-Yun Lin

      Affiliations

    • Department of Pharmacology, College of Medicine, Chang Gung University, Taiwan, Republic of China
    • ,
  • Phei-Lang Chang

      Affiliations

    • Chang Gung Bioinformatics Center, Department of Urology, Chang Gung Memorial Hospital, Taiwan, Republic of China
    • ,
  • Chih-Hao Chang

      Affiliations

    • Department of Basic Medical Sciences, College of Medicine, Chang Gung University, Taiwan, Republic of China
    • ,
  • Benjamin Yat-Ming Yung

      Affiliations

    • Department of Health Technology and Informatics, Hong Kong Polytechnic University, Hong Kong, Special Administrative Region of the People's Republic of China
    • Corresponding Author InformationCorrespondence: Department of Health Technology and Informatics, Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, Special Administrative Region of the People's Republic of China (telephone: 852 3400 8683; FAX: 852 2362 4365)

Received 8 April 2009

References 

  1. Raghaven D, Shipley WU, Garnick MB, et al. Biology and management of bladder cancer. New Engl J Med. 1990;322:1129
  2. Newling DW. Preventing recurrence and progression in superficial bladder cancer. Curr Opin Urol. 1996;6:272
  3. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol. 2001;165:600
  4. Konety B, Lotan Y. Urothelial bladder cancer: biomarkers for detection and screening. BJU Int. 2008;102:1234
  5. van Tilborg AA, Bangma CH, Zwarthoff EC. Bladder cancer biomarkers and their role in surveillance and screening. Int J Urol. 2009;16:23
  6. Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer. J Urol. 1999;161:388
  7. Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol Semin Orig Invest. 2006;24:326
  8. Quek ML, Sanderson K, Daneshmand S, et al. New molecular markers for bladder cancer detection. Curr Opin Urol. 2004;14:259
  9. Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991;252:706
  10. Kobayashi H, Suzuki M, Hirashima Y, et al. The protease inhibitor birkunin, a novel anti-metastatic agent. Biol Chem. 2003;384:749
  11. Matsuzaki H, Kobayashi H, Yagyu T, et al. Birkunin inhibits lipopolysaccharide-induced tumor necrosis factor alpha induction in macrophages. Clin Diagn Lab Immunol. 2004;11:1140
  12. Matsuzaki H, Kobayashi H, Tanakan Y, et al. Bikunin target genes in ovarian cancer cells identified by microarray analysis. J Biol Chem. 2003;278:14640
  13. Lin CY, Tsui KH, Yu CC, et al. Searching cell secreted proteomes for potential urinary bladder tumor markers. Proteomics. 2006;6:4381
  14. Greene FL, Page DL, Flemming ID, et al. AJCC Cancer Staging Manual. 6th ed.. New York: Springer-Verlag; 2002;
  15. Mostofi FK, Davis CJ, Sesterhenn IA. Histological typing of urinary bladder tumors. International Histological Classification of Tumors. Geneva: World Health Organization; 1998;
  16. Shevchenko A, Wilm M, Vorm O, et al. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 1996;68:850
  17. Schwamborn K, Krieg RC, Grosse J, et al. Serum proteomic profiling in patients with bladder cancer. Eur Urol. 2009;Epub ahead of print
  18. Fries E, Blom AM. Bikunin—not just a plasma proteinase inhibitor. Int J Biochem Cell Biol. 2000;32:125
  19. Yagyu T, Kobayashi H, Matsuzaki H, et al. Enhanced spontaneous metastasis in bikunin-deficient mice. Int J Cancer. 2006;118:2322
  20. Kobayashi H, Suzuki M, Tanaka Y, et al. Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways. J Biol Chem. 2001;276:2015
  21. Andreasen PA, Kjoller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997;72:1
  22. Duffy ML. Proteases as prognostic markers in cancer. Clin Cancer Res. 1996;2:613
  23. Duffy MJ, O'Grady P, Devaney D, et al. Urokinase-plasminogen activator, a marker for aggressive breast cancers. Cancer. 1988;62:531
  24. Duffy MJ, Reilly D, O'Sullivan C, et al. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 1990;50:6827
  25. Oka T, Ishida T, Nishino T, et al. Immunohistochemical evidence for Urokinase plasminogen activator in primary and metastatic tumors for pulmonary carcinoma. Cancer Res. 1991;51:3522
  26. Hasui Y, Marutsuka K, Suzumiya J, et al. The content of urokinase-type plasminogen activator as a prognostic factor in bladder cancer. Int J Cancer. 1992;50:871

 Study received approval from the review board for the protection of human subjects.

 Supported by Chang Gung Memorial Hospital Research Funding Grants CMRPD150103 and CMRPG370121, National Science Council (Republic of China) Grant NSC96-2320-B-182-027-MY3 and HKPolyU Grant 155.B1.DD52.

PII: S0022-5347(09)02322-2

doi: 10.1016/j.juro.2009.08.109

The Journal of Urology
Volume 183, Issue 1 , Pages 339-344 , January 2010

Article Tools

* Image Usage & Resolution